Amarantus BioScience Opens Investigational New Drug (IND) Application With the U.S. Food and Drug Administration Allowing the Start of a Phase 2b Program of Eltoprazine in Parkinson's Disease Levodopa-Induced Dyskinesia

Enrollment and Dosing for a 60-Patient Clinical Study on Track to Commence 2Q 2015 SAN FRANCISCO, March 26, 2015 (GLOBE NEWSWIRE) — Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology c…Read More »

Amarantus to Present at the Neurotech Investing and Partnering Conference on Tuesday, April 7, 2015

- CEO, Gerald E. Commissiong to Present During the Treatments for Alzheimer’s and Cognitive Disorders Session on April 7, 2015 From 10:30-11:30 a.m. PDT – SAN FRANCISCO and GENEVA, March 23, 2015 (GLO…Read More »

Amarantus to Present Positive Alzheimer's Disease Biomarker Data on the LymPro Test(R) at the 12th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

SAN FRANCISCO and GENEVA, Feb. 23, 2015 (GLOBE NEWSWIRE) — Amarantus BioSciences Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on developing diagnostics in neurology, and therapeutic p…Read More »

Amarantus Announces First Alzheimer's Biomarker Services Collaboration for LymPro Test(R) With Anavex Life Sciences Corp.

Investigational Alzheimer’s drug candidate ANAVEX 2-73 and drug combination ANAVEX PLUS pharmacodynamic activity to be evaluated using Amarantus’ LymPro Test® in blood samples from Alzheimer’s disease…Read More »

Amarantus Announces Publication in BRAIN of Eltoprazine Phase 2a Clinical Study for Treating Parkinson's Disease Levodopa-Induced Dyskinesia

Eltoprazine demonstrated significant beneficial anti-dyskinesia effect at 5 and 7.5 mg doses, with no reduction of levodopa efficacy Eltoprazine was well tolerated at all dose levels, with no major ad…Read More »
Amarantus Bioscience Holdings, Inc. (OTCQB: AMBS) is a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis (programmed cell death).

Company Information

Company Website: http://www.amarantus.com/
Company Headquarters

Amarantus BioScience Holdings, Inc.
655 Montgomery Street
Suite 900
San Francisco, CA 94111
Phone: (415) 688-4484
Fax: (408) 852-4427
info@amarantus.com

Media and Investor Relations Contact

Jenene Thomas Communications, LLC
Jenene Thomas, Investor Relations and Corporate Communications Advisor
Phone: (908) 938-1475
jenene@jenenethomascommunications.com

Forward Looking Statements

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are forward-looking statements." These forward-looking statements generally are identified by the words believes," project," expects," anticipates," estimates," intends," strategy," plan," may," will," would," will be," will continue," will likely result," and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.

This Blog is official and sanctioned by Amarantus BioScience | See Disclaimer | See Privacy Policy

Get Amarantus BioScience Blog Post Alerts